SEC Form 4 · accession 0001104659-18-033905
Aralez Pharmaceuticals Inc. · ARLZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James Patrick Tursi
Officer — Chief Medical Officer
Period of report
May 14, 2018
Accepted (ET)
May 16, 2018 · 7:49 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001660719
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares, without par valueF2 | May 14, 2018 | S | 9,348 | $0.5222 | D | 242,052 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This represents shares sold by the issuer on behalf of the reporting person pursuant to an instruction made in accordance with Rule 10b5-1 for payment of withholding tax liability incurred upon the vesting of 27,730 restricted stock units, which were previously granted on May 11, 2017 and which vested on May 11, 2018.
- F2This transaction was executed in multiple trades at prices ranging from $0.5206 to $0.5269. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.